SV2016005351A - Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble - Google Patents
Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa solubleInfo
- Publication number
- SV2016005351A SV2016005351A SV2016005351A SV2016005351A SV2016005351A SV 2016005351 A SV2016005351 A SV 2016005351A SV 2016005351 A SV2016005351 A SV 2016005351A SV 2016005351 A SV2016005351 A SV 2016005351A SV 2016005351 A SV2016005351 A SV 2016005351A
- Authority
- SV
- El Salvador
- Prior art keywords
- same
- indolina
- guanilate
- indano
- activators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
LA PRESENTE INVENCIÓN PROPORCIONA UN COMPUESTO DE LA FÓRMULA (1) O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO: (VER FORMULA); UN MÉTODO PARA FABRICAR LOS COMPUESTOS DE LA INVENCIÓN, Y SUS USOS TERAPÉUTICOS. LA PRESENTE INVENCIÓN ADEMÁS PROPORCIONA UNA COMBINACIÓN DE AGENTES FARMACOLÓGICAMENTE ACTIVOS Y UNA COMPOSICIÓN FARMACÉUTICA
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462020166P | 2014-07-02 | 2014-07-02 | |
US201562168627P | 2015-05-29 | 2015-05-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
SV2016005351A true SV2016005351A (es) | 2018-08-20 |
Family
ID=53724402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV2016005351A SV2016005351A (es) | 2014-07-02 | 2016-12-22 | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble |
Country Status (26)
Country | Link |
---|---|
US (2) | US10208018B2 (es) |
EP (1) | EP3164395B1 (es) |
JP (1) | JP2017519835A (es) |
KR (1) | KR20170021345A (es) |
CN (1) | CN106470985A (es) |
AP (1) | AP2016009609A0 (es) |
AU (1) | AU2015283617B2 (es) |
BR (1) | BR112016030733A2 (es) |
CA (1) | CA2953885A1 (es) |
CL (1) | CL2016003329A1 (es) |
CO (1) | CO2017000222A2 (es) |
CR (1) | CR20170003A (es) |
CU (1) | CU20160192A7 (es) |
EA (1) | EA030634B1 (es) |
EC (1) | ECSP17007208A (es) |
ES (1) | ES2732758T3 (es) |
GT (1) | GT201600269A (es) |
IL (1) | IL249406A0 (es) |
MX (1) | MX2016017325A (es) |
PE (1) | PE20170323A1 (es) |
PH (1) | PH12016502539A1 (es) |
SG (1) | SG11201610226SA (es) |
SV (1) | SV2016005351A (es) |
TN (1) | TN2016000556A1 (es) |
TW (1) | TW201625584A (es) |
WO (1) | WO2016001875A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201625584A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
JP2018529745A (ja) | 2015-10-06 | 2018-10-11 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Nrf2レギュレーターとしてのビアリールピラゾール |
KR20180095594A (ko) * | 2015-12-18 | 2018-08-27 | 노파르티스 아게 | 인단 유도체 및 가용성 구아닐레이트 시클라제 활성화제로서의 그의 용도 |
WO2017201683A1 (en) * | 2016-05-25 | 2017-11-30 | Merck Sharp & Dohme Corp. | Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists |
AU2017300558B2 (en) * | 2016-07-22 | 2021-02-25 | Toa Eiyo Ltd. | Therapeutic agent for glaucoma |
WO2018069148A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
EP3787610A1 (en) | 2018-04-30 | 2021-03-10 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
EA202092680A1 (ru) | 2018-05-15 | 2021-04-13 | Байер Акциенгезельшафт | 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон |
EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
CA3108551A1 (en) | 2018-08-06 | 2020-02-13 | Nicox S.A. | Nitric oxide releasing phosphodiesterase type 5 inhibitor |
US20220128561A1 (en) | 2019-01-17 | 2022-04-28 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc) |
WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2336807C (en) | 1998-07-08 | 2010-04-13 | Aventis Pharma Deutschland Gmbh | Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
EP1420023B1 (en) | 2001-01-24 | 2006-12-06 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Use of fused pyrazolyl compounds for the preparation of a medicament for treating hypertension |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
US8247563B2 (en) * | 2006-12-11 | 2012-08-21 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors |
DE102007015035A1 (de) | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Substituierte Dibenzoesäure-Derivate und ihre Verwendung |
CA2697678C (en) | 2007-08-31 | 2015-06-23 | Kalsi Engineering, Inc. | Rotary seal with improved film distribution |
CA2698332C (en) * | 2007-09-06 | 2012-08-21 | Merck Sharp & Dohme Corp. | Pyrazole derivatives as soluble guanylate cyclase activators |
WO2009068652A1 (en) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators |
TW200938529A (en) | 2007-12-03 | 2009-09-16 | Smithkline Beecham Corp | Compounds |
JP5432890B2 (ja) | 2008-04-04 | 2014-03-05 | 武田薬品工業株式会社 | 複素環誘導体及びその用途 |
DE102008018675A1 (de) | 2008-04-14 | 2009-10-15 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclisch substituierte Carbonsäure-Derivate und ihre Verwendung |
WO2010015653A1 (en) | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Pyrimidine derivatives as activators of soluble guanylate cyclase |
CN102414194A (zh) | 2009-02-26 | 2012-04-11 | 默沙东公司 | 可溶性鸟苷酸环化酶激活剂 |
DE102009012314A1 (de) | 2009-03-09 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung |
DE102009046115A1 (de) | 2009-10-28 | 2011-09-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 3-Phenylpropansäuren und ihre Verwendung |
MY159697A (en) | 2010-02-05 | 2017-01-13 | Adverio Pharma Gmbh | Sgc stimulators or sgc activators alone and in combination with pde5 inhibitors for the treatment of cystic fibrosis |
WO2011095553A1 (en) | 2010-02-05 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft | Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction |
HUE025162T2 (en) | 2010-05-26 | 2016-04-28 | Adverio Pharma Gmbh | Use of sGC stimulators, sGC activators alone or in combination with PDE5 inhibitors to treat systemic sclerosis (SSc). |
CA2803688A1 (en) | 2010-06-25 | 2011-12-29 | Bayer Intellectual Property Gmbh | Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes |
WO2012058132A1 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
BR112013013663A2 (pt) | 2010-12-07 | 2016-09-06 | Bayer Ip Gmbh | ácidos 1-benzilcicloalquilcarboxílicos substituídos e sua utilização |
US8569339B2 (en) | 2011-03-10 | 2013-10-29 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
WO2013025425A1 (en) | 2011-08-12 | 2013-02-21 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
EP2594270A3 (en) | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
PT2892891T (pt) | 2012-09-07 | 2019-11-05 | Boehringer Ingelheim Int | Alcoxi pirazoles como ativadores de guanilato ciclase solúvel |
JP5565645B1 (ja) | 2012-10-09 | 2014-08-06 | Dic株式会社 | バンプクッション |
US10265314B2 (en) | 2013-07-25 | 2019-04-23 | Bayer Pharma Aktiengesellschaft | SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis |
RU2016112542A (ru) | 2013-09-05 | 2017-10-06 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Новые активаторы растворимой гуанилатциклазы и их применение |
WO2015095515A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
TW201625586A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 環己烯-1-基-吡啶-2-基-1h-吡唑-4-羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
TW201625601A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 噻吩-2-基-吡啶-2-基-1h-吡唑-4-羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
TW201625584A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
-
2015
- 2015-07-01 TW TW104121398A patent/TW201625584A/zh unknown
- 2015-07-02 AP AP2016009609A patent/AP2016009609A0/en unknown
- 2015-07-02 CA CA2953885A patent/CA2953885A1/en not_active Abandoned
- 2015-07-02 AU AU2015283617A patent/AU2015283617B2/en not_active Ceased
- 2015-07-02 WO PCT/IB2015/055006 patent/WO2016001875A1/en active Application Filing
- 2015-07-02 US US15/320,810 patent/US10208018B2/en active Active
- 2015-07-02 ES ES15742103T patent/ES2732758T3/es active Active
- 2015-07-02 BR BR112016030733A patent/BR112016030733A2/pt not_active Application Discontinuation
- 2015-07-02 JP JP2017520035A patent/JP2017519835A/ja not_active Ceased
- 2015-07-02 EA EA201692542A patent/EA030634B1/ru not_active IP Right Cessation
- 2015-07-02 SG SG11201610226SA patent/SG11201610226SA/en unknown
- 2015-07-02 MX MX2016017325A patent/MX2016017325A/es unknown
- 2015-07-02 TN TN2016000556A patent/TN2016000556A1/en unknown
- 2015-07-02 KR KR1020177002515A patent/KR20170021345A/ko unknown
- 2015-07-02 EP EP15742103.3A patent/EP3164395B1/en active Active
- 2015-07-02 CN CN201580036394.9A patent/CN106470985A/zh active Pending
- 2015-07-02 PE PE2016002818A patent/PE20170323A1/es unknown
- 2015-07-02 CR CR20170003A patent/CR20170003A/es unknown
-
2016
- 2016-12-06 IL IL249406A patent/IL249406A0/en unknown
- 2016-12-19 PH PH12016502539A patent/PH12016502539A1/en unknown
- 2016-12-22 SV SV2016005351A patent/SV2016005351A/es unknown
- 2016-12-23 GT GT201600269A patent/GT201600269A/es unknown
- 2016-12-26 CL CL2016003329A patent/CL2016003329A1/es unknown
- 2016-12-28 CU CUP2016000192A patent/CU20160192A7/es unknown
-
2017
- 2017-01-11 CO CONC2017/0000222A patent/CO2017000222A2/es unknown
- 2017-02-02 EC ECIEPI20177208A patent/ECSP17007208A/es unknown
-
2018
- 2018-12-11 US US16/216,420 patent/US10550102B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP3164395B1 (en) | 2019-03-27 |
IL249406A0 (en) | 2017-02-28 |
CO2017000222A2 (es) | 2017-05-19 |
US10550102B2 (en) | 2020-02-04 |
SG11201610226SA (en) | 2017-01-27 |
US20190119254A1 (en) | 2019-04-25 |
CR20170003A (es) | 2017-03-10 |
JP2017519835A (ja) | 2017-07-20 |
PH12016502539A1 (en) | 2017-04-10 |
AU2015283617B2 (en) | 2017-10-05 |
CA2953885A1 (en) | 2016-01-07 |
CU20160192A7 (es) | 2017-04-05 |
MX2016017325A (es) | 2017-05-01 |
ES2732758T3 (es) | 2019-11-25 |
EP3164395A1 (en) | 2017-05-10 |
GT201600269A (es) | 2018-12-18 |
AU2015283617A1 (en) | 2017-01-12 |
KR20170021345A (ko) | 2017-02-27 |
US10208018B2 (en) | 2019-02-19 |
TN2016000556A1 (en) | 2018-04-04 |
ECSP17007208A (es) | 2018-09-30 |
CL2016003329A1 (es) | 2017-06-09 |
EA030634B1 (ru) | 2018-09-28 |
CN106470985A (zh) | 2017-03-01 |
AP2016009609A0 (en) | 2016-12-31 |
PE20170323A1 (es) | 2017-04-21 |
WO2016001875A1 (en) | 2016-01-07 |
US20170197940A1 (en) | 2017-07-13 |
EA201692542A1 (ru) | 2017-04-28 |
TW201625584A (zh) | 2016-07-16 |
BR112016030733A2 (pt) | 2017-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2016005351A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
SV2016005137A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
NI201600058A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
UY35273A (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn | |
GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
AR103680A1 (es) | Inhibidores selectivos de bace1 | |
CU20130139A7 (es) | Derivados glocósidos y usos de los mismos | |
SV2016005313A (es) | Derivados de carboxamida | |
DOP2017000107A (es) | Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos | |
UY36123A (es) | Derivados de carboxamida | |
DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
UY35209A (es) | Compuestos tricíclicos | |
UY35211A (es) | Compuestos tricíclicos | |
CL2020001277A1 (es) | Derivados de piridinona y su uso como inhibidores selectivos de alk-2. | |
UY36084A (es) | Activadores de herg policíclicos | |
CU20160170A7 (es) | Derivados de carboxamida | |
UY35672A (es) | Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos | |
UY35792A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
CU20140127A7 (es) | Moduladores de la ruta del complemento y usos de los mismos |